<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452828</url>
  </required_header>
  <id_info>
    <org_study_id>1986-031</org_study_id>
    <secondary_id>TR701-123</secondary_id>
    <nct_id>NCT01452828</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetics and Safety Study in Subjects With Renal Impairment</brief_title>
  <official_title>A Phase I Open-Label Study With 200 mg Intravenous TR-701 Free Acid to Assess Safety and Pharmacokinetics in Advanced Renal Impairment Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trius Therapeutics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trius Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the single dose pharmacokinetics (PK) and safety of
      TR701 FA in subjects with advance renal impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the pharmacokinetics (PK) and evaluate the safety of intravenous (IV) infusion of
      TR-701 free acid (FA) in subjects with advanced renal impairment compared with matched
      control subjects with normal renal function
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite (or Profile) of Pharmacokinetics</measure>
    <time_frame>predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 36, 48, 60, 72 hours post-dose</time_frame>
    <description>Cmax, Area Under Curve, Tmax t1/2 will be compared between each renal group and the control group, including calculation of geometric mean ratio and corresponding 90% confidence intervals.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Renal Impairment Nondialyzed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal Impairment Dialyzed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA single infusion</intervention_name>
    <description>Single IV infusion, 200 mg daily for 7 days</description>
    <arm_group_label>Renal Impairment Nondialyzed</arm_group_label>
    <other_name>Tedizolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA</intervention_name>
    <description>Two separate infusions of 200 mg</description>
    <arm_group_label>Renal Impairment Dialyzed</arm_group_label>
    <other_name>Tedizolid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TR-701 FA</intervention_name>
    <description>Single IV infusion, 200 mg daily for 7 days</description>
    <arm_group_label>Matched Control</arm_group_label>
    <other_name>Tedizolid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 18.0 and 40.0 kg/m2 inclusive

          -  Male or female subjects between 18 and 75 years of age

          -  Stable dosage of medication for 30 days

          -  for dialysis patients, receiving chronic and stable maintenance hemodialysis for at
             least 3 months

        Exclusion Criteria:

          -  Functioning transplanted solid organ

          -  High tyramine diet

          -  Significant, unstable, or life-threatening condition or organ or system condition or
             disease, other than kidney disease in renal subjects
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Prokocimer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Trius Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trius Investigator Site 001</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trius Investigator Site 002</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>October 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torezolid phosphate</mesh_term>
    <mesh_term>Torezolid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

